CRNX supply chain intelligence for Crinetics Pharmaceuticals, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Crinetics Pharmaceuticals, Inc. (CRNX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| BIOLOGICS | BIOLOGICS | 90% | An enrollment form is an official document containing both HCP and patient consent, submitted to CrinetiCARE or specialty pharmacies (Orsini or Biologics) to initiate a patient on Palsonify. |
| JEFF-KNIGHT | JEFF-KNIGHT | 90% | On April 10, 2026, the Company entered into an Independent Consultant Agreement (the “Consulting Agreement”) with Mr. Knight, pursuant to which Mr. Knight agreed to provide certain services to the Company |
| ORSINI | ORSINI | 90% | An enrollment form is an official document containing both HCP and patient consent, submitted to CrinetiCARE or specialty pharmacies (Orsini or Biologics) to initiate a patient on Palsonify. |
| RADIONETICS-ONCOLOGY-INC | RADIONETICS-ONCOLOGY-INC | 90% | we entered into a Collaboration and License Agreement with Radionetics, or the Radionetics License, granting Radionetics an exclusive world-wide license to certain targets for the development of radi… |
| SANWA-KAGAKU-KENKYUSHO-CO-LTD | SANWA-KAGAKU-KENKYUSHO-CO-LTD | 90% | In February 2022, we entered into the SKK License, pursuant to which we granted SKK an exclusive license to develop and commercialize paltusotine in Japan. Under the SKK License, SKK is responsible f… |
| OHIO-UNIVERSITY | OHIO-UNIVERSITY | 80% | In May 2026, Crinetics entered into an exclusive license agreement with Ohio University to develop an early preclinical growth hormone receptor antagonist for the treatment of acromegaly. |
| VRDN | Viridian Therapeutics, Inc. | 72% | Reciprocal relationship from VRDN graph: Reciprocal relationship from CRNX graph: Reciprocal relationship from VRDN graph: Reciprocal relationship from CRNX graph: Reciprocal relationship from VRDN g… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CELLULAR-LONGEVITY-INC | CELLULAR-LONGEVITY-INC | 92% | CRN01941, a separate SST2 agonist licensed to Cellular Longevity Inc., doing business as Loyal, for veterinary use, or the Loyal License. |
| CRINETICARE | CRINETICARE | 90% | An enrollment form is an official document containing both HCP and patient consent, submitted to CrinetiCARE or specialty pharmacies (Orsini or Biologics) to initiate a patient on Palsonify. |
| LLY | Eli Lilly and Company | 85% | Reciprocal relationship from LLY graph: Reciprocal relationship from CRNX graph: Radionetics announced the formation of a strategic partnership with Eli Lilly and Company, or Lilly. Under the terms o… |
| LLY | Eli Lilly and Company | 85% | Radionetics announced the formation of a strategic partnership with Eli Lilly and Company, or Lilly. Under the terms of the agreement, Radionetics received an upfront cash payment of $140 million and… |
| AZN | AstraZeneca PLC | 72% | products in relation to alternative treatments and therapies; • our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement from government healthcare programs, incl… |
| AZN | AstraZeneca PLC | 72% | Reciprocal relationship from AZN graph: Reciprocal relationship from CRNX graph: Reciprocal relationship from AZN graph: Reciprocal relationship from CRNX graph: products in relation to alternative t… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from CRNX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from CRNX graph: Reciprocal relationship from NVSE… |
| NVSEF | Novartis AG | 72% | products in relation to alternative treatments and therapies; • our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement from government healthcare programs, incl… |
| ALEXION-PHARMACEUTICALS-INC-ASTRAZENECA-PLC | ALEXION-PHARMACEUTICALS-INC-ASTRAZENECA-PLC | 62% | products in relation to alternative treatments and therapies; • our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement from government healthcare programs, incl… |
| IPSEN-BIOPHARMACEUTICALS-INC | IPSEN-BIOPHARMACEUTICALS-INC | 62% | products in relation to alternative treatments and therapies; • our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement from government healthcare programs, incl… |
| LEERINK-PARTNERS-LLC | LEERINK-PARTNERS-LLC | 62% | ry for successful product commercialization. Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had a history of successfully devel… |
| RECORDATI-RARE-DISEASES-INC | RECORDATI-RARE-DISEASES-INC | 62% | products in relation to alternative treatments and therapies; • our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement from government healthcare programs, incl… |
| SANWA-KAGAKU-KENKYUSHO-CO-LTD | SANWA-KAGAKU-KENKYUSHO-CO-LTD | 62% | eighted-average discount rate was 8.6 %. Cash paid for amounts included in the measurement of lease liabilities for operating cash flow from operating leases was $ 4.5 million, $ 1.6 million, and $ 1… |
| TERSERA-THERAPEUTICS-INC | TERSERA-THERAPEUTICS-INC | 62% | products in relation to alternative treatments and therapies; • our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement from government healthcare programs, incl… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| CRNX-DEBT | Debt stack $47.9M | 90% | Market cache reports total debt of $47.9M. |
| CRNX-DEBT-8861 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2018-12-31. |
| CRNX-DEBT-13804 | Warrants outstanding: 3407285 | 90% | xbrl warrant detail from xbrl 2023-08-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| CRNX-OWNER-FMR-LLC | FMR LLC | 90% | 13F overlay lists FMR LLC as top holder; 245 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| CHRS | Coherus Oncology, Inc. | 100.00 | 2 | |
| HTGC | Hercules Capital, Inc. | 100.00 | 2 | |
| NVO | Novo Nordisk A/S | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| DEO | Diageo plc | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| ALLO | Allogene Therapeutics, Inc. | 100.00 | 2 | |
| AXSM | Axsome Therapeutics, Inc. | 100.00 | 2 | |
| FHTX | Foghorn Therapeutics Inc. | 100.00 | 2 | |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 100.00 | 2 | |
| CCCC | C4 Therapeutics, Inc. | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| AKTS | Aktis Oncology, Inc. | 100.00 | 2 | |
| DAWN | Day One Biopharmaceuticals Inc | 100.00 | 2 | |
| EDSA | Edesa Biotech, Inc. | 100.00 | 2 | |
| VEEV | Veeva Systems Inc. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| SDGR | Schrödinger, Inc. | 100.00 | 2 |